News
17h
Zacks.com on MSNLilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...
19h
InvestorsHub on MSNNovo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes TreatmentsNovo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...
Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
Shares of American Eagle Outfitters are tumbling before Wednesday's opening bell after the retailer withdrew its financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results